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Both genetic and environmental factors are involved in the etiology of obesity and the associated lipid disturbances. We
determined whether acquired obesity is associated with changes in global serum lipid profiles independent of genetic factors
in young adult monozygotic (MZ) twins. 14 healthy MZ pairs discordant for obesity (10 to 25 kg weight difference) and ten
weight concordant control pairs aged 24–27 years were identified from a large population-based study. Insulin sensitivity was
assessed by the euglycemic clamp technique, and body composition by DEXA (% body fat) and by MRI (subcutaneous and
intra-abdominal fat). Global characterization of lipid molecular species in serum was performed by a lipidomics strategy using
liquid chromatography coupled to mass spectrometry. Obesity, independent of genetic influences, was primarily related to
increases in lysophosphatidylcholines, lipids found in proinflammatory and proatherogenic conditions and to decreases in
ether phospholipids, which are known to have antioxidant properties. These lipid changes were associated with insulin
resistance, a pathogonomic characteristic of acquired obesity in these young adult twins. Our results show that obesity,
already in its early stages and independent of genetic influences, is associated with deleterious alterations in the lipid
metabolism known to facilitate atherogenesis, inflammation and insulin resistance.
Citation: Pietila¨inen KH, Sysi-Aho M, Rissanen A, Seppa¨nen-Laakso T, Yki-Ja¨rvinen H, et al (2007) Acquired Obesity Is Associated with Changes in the
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INTRODUCTION
Obesity increases the risk of cardiovascular diseases and diabetes
[1] especially when the extra fat is accumulated to central and
intra-abdominal depots [2,3]. The increased cardiometabolic risk
in obesity is at least partly mediated through atherogenic
dyslipidemia characterized by an increase in plasma triglycerides,
large very low density lipoprotein (VLDL) particles, small dense
low density lipoprotein (LDL) particles as well as low concentra-
tions of high density (HDL) cholesterol [4]. It is also recognized
that changes in the function of individual lipids due to
peroxidation, imbalanced fatty acid composition or their altered
flux from peripheral tissues may contribute to development of
atherosclerosis and diabetes [5].
The advent of novel analytical and information technologies for
handling large volumes of data has made it feasible to characterize
complex mixtures of lipids in body fluids and tissues and relate
them to other entities of biological systems [5,6]. Therefore,
lipidomics as a branch of metabolomics may provide powerful
tools for characterization of global lipid profiles and identification
of previously unknown changes in lipid metabolism in complex
phenotypes such as those related to obesity [7–9].
The origin of obesity and related dyslipidemias is multifactorial
[10]. Not all obese individuals develop dyslipidemia and not all
dyslipidemic patients are obese. While environmental and lifestyle
factors play a key role in the development of obesity, genetic
variation may determine an individual’s susceptibility to body fat
accumulation and lipid disturbances [10]. Cross-sectional studies
comparing lipid profiles in obese vs. non-obese humans do not
permit unequivocal distinction between genetic versus environ-
mental and life-style effects. This can best be done by studying
monozygotic (MZ) twins discordant for obesity. MZ twins are
genetically identical at the sequence level and any differences
between the co-twins are thus attributable to environmental
factors [11]. Environmental factors are here considered very
broadly, including i.e. possible prenatal exposures and effects
inducing epigenetic changes. The co-twin design controls for age,
gender, childhood socioeconomic background and other environ-
mental experiences and exposures.
In a previous study of young adult obesity-discordant but
otherwise healthy MZ twin pairs we have shown that the degree of
obesity correlates with increases in visceral and liver fat deposition
[12]. These adverse effects were associated with abnormalities in
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expression of fatty acid transport proteins [13] and increased
expression of inflammation markers in the adipose tissue [14,15].
We then hypothesized that obesity-discordant twins would
differ for the levels of specific serum lipid molecular species, and
that these lipid species may provide further clues about the early
mechanisms and biomarkers associated with acquired obesity
and related complications. In this paper we report the results of
lipidomics analyses of 14 pairs of MZ twins highly discordant
for obesity. We show that acquired obesity primarily relates to
increases in lysophosphatidylcholines, constituents of an athero-
genic lipid profile and decreases in ether phospholipids,
lipids with anti-oxidative properties. Sphingomyelins with long
chain fatty acids remain very similar in the weight-discordant
co-twins.
METHODS
Subjects
The participants were recruited from a population-based longitu-
dinal survey of five consecutive birth cohorts (1975–1979) of twins,
their siblings and parents, identified through the national
population registry of Finland [16]. Twin pairs included in the
current study were enrolled based on their responses to questions
on weight and height at age 23–27 years [12–15,17,18]. After
screening of all MZ twin pairs (N= 658), we identified 18 pairs
with a reported body mass index (BMI) difference of at least four
kg/m2, such that one co-twin was non-obese (BMI approximately
25 kg/m2), while the other was obese (BMI approximately 30 kg/
m2). Fourteen of these pairs (eight male and six female pairs)
participated in the present study. We also studied ten randomly
selected weight-concordant MZ pairs (reported BMI difference of
less than two kg/m2, two male and three female over-weight pairs,
three male and two female normal-weight pairs). The measured
BMI differences ranged from 3.3 to 10.1 kg/m2 in the discordant
and from 0.0 to 2.3 kg/m2 in the concordant pairs. Discordant
pairs were of the same age (mean6SD 25.661.2 years) as the
concordant pairs (25.761.2 years).
The subjects were healthy (based on medical history and clinical
examination by a physician (KHP), normotensive and did not use
any medications except contraceptives. Their psychiatric health
was confirmed by a structured psychiatric interview ‘Semi-
structured assessment for the genetics of alcohol interview
instrument’ (SSAGA) [19], supplemented by the eating disorders
sections of the Structured Clinical Interview for DSM-IV-TR
(SCID). The SSAGA provides diagnoses of common psychiatric
conditions including depression and substance abuse and de-
pendence based on Diagnostic and Statistical Manual of Mental
Disorders (DSM) and International Classification of Diseases
(ICD) diagnostic criteria. The twins were interviewed by telephone
by two experienced interviewers, such that each member of twin
pair was interviewed by a different interviewer; the interviewers
were blind as to the clinical details and weight status of the twin.
All twins had been weight-stable for at least 3 months prior to
the study. Females were scheduled to attend during the follicular
phase of their menstrual cycle. All the concordant pairs were
nonsmokers, but four out of 14 obesity-discordant pairs were
discordant for smoking. In three pairs, the one who smoked more
was leaner, but in one pair, the co-twin who smoked more was
heavier. Monozygosity was confirmed by genotyping of ten
informative genetic markers [17]. The subjects provided written
informed consent. The protocol was designed and performed
according to the principles of the Helsinki Declaration and was
approved by the Ethical Committee of the Helsinki University
Central Hospital.
Clinical assessments
All subjects were studied after an overnight fast starting at 8 a.m.
Five ml venous blood samples were obtained from which plasma
with ethylenediaminetetraacetate (EDTA) and serum were
separated by centrifugation, frozen immediately at 220uC, moved
to 280uC within 6 hours and stored until analysis. Body
composition was measured by dual-energy x-ray absorptiometry
(DEXA) (Lunar Prodigy, Madison, WI, software version 2.15)
[20]. Subcutaneous (SC) and intra-abdominal (IA) fat were
determined by magnetic resonance imaging (MRI) of 16 transaxial
scans reaching from 8 cm above to 8 cm below the fourth and fifth
lumbar interspace [12]. Three day food diaries completed by the
subjects were reviewed by a trained nutritionist, and analyzed by
using the program DIET32, which is based on a national database
for food composition (Fineli) (http://www.ktl.fi/fineli/).
Insulin sensitivity
Whole body insulin sensitivity was determined by the euglycemic
hyperinsulinemic clamp technique [21]. Two 18-gauge catheters
(Venflon; Viggo-Spectramed, Helsingborg, Sweden) were inserted,
one in an antecubital vein for infusion of insulin and glucose, and
another retrogradely in a heated hand vein to obtain arterialised
venous blood for measurement of glucose concentrations every
5 min and serum free insulin concentration every 30 min. Regular
human insulin (Insulin Actrapid; Novo Nordisk, Denmark) was
infused in a primed-continuous fashion. The rate of the continuous
insulin infusion was 40 mU/m2?min (1 mU/kg?min) for 120 min.
Normoglycemia was maintained by adjusting the rate of a 20%
glucose infusion based on plasma glucose measurements from
arterialised venous blood every 5 min. Whole body insulin
sensitivity (the M-value, expressed as mg/kg fat free mass per
minute) was determined from the glucose infusion rate needed to
maintain normoglycemia after correction for changes in the
glucose pool size [21]. Since hepatic glucose production is
maximally suppressed in non-diabetic subjects already at an
insulin concentration achieved during infusion of insulin at a rate
of 0.5 mU/kg?min [22], the M-value mostly reflects glucose
uptake. Plasma glucose concentrations were measured in duplicate
with the glucose oxidase method (Glucose Analyzer II; Beckman
Instruments, Fullerton, CA, USA) [23]. Serum free insulin
concentrations were determined with radioimmunoassay (Phade-
seph Insulin RIA, Pharmacia & Upjohn Diagnostics, Uppsala,
Sweden) after precipitation with polyethylene glycol [24].
Clinical chemistry
Serum total, high density lipoprotein cholesterol (HDL) and
triglyceride concentrations were measured with respective enzymatic
kits from Roche Diagnostics using an autoanalyzer (Roche
Diagnostics Hitachi 917, Hitachi Ltd, Tokyo, Japan). Low density
lipoprotein cholesterol (LDL) concentrations were calculated using
the formula of Friedewald [25]. Serum leptin concentrations were
measured using enzyme-linked immunoassays (Quantikine R&D
Systems, Minneapolis, MN, USA) and adiponectin concentrations
using the ELISA kit from B-Bridge International (San Jose, CA,
USA). High-sensitivity C-reactive protein (CRP) was measured using
a sensitive double antibody sandwich ELISA with rabbit antihuman
CRP and peroxidase conjugated rabbit anti-human CRP.
Lipid nomenclature
Lipids from the lipidomic analysis were named according to Lipid
Maps (http://www.lipidmaps.org) [26]. For example, lysopho-
sphatidylcholine with 16:0 fatty acid chain was named as
monoacyl-glycerophosphocholine GPCho(16:0/0:0). In case the
Lipidomics Study in Twins
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fatty acid composition was not determined, total number of carbons
and double bonds was marked. For example, a phosphatidylcholine
species GPCho(16:0/20:4) is represented as GPCho(36:4). However,
GPCho(36:4) could also represent other molecular species, for
example GPCho(20:4/16:0) or GPCho(18:2/18:2).
Lipidomics analysis
To examine the lipid phenotypes of the twin pairs, the Ultra
Performance Liquid Chromatography Mass Spectrometry
(UPLC/MS) based lipidomics analysis was performed. The
applied platform affords broad screening of multiple lipid classes
from total lipid extracts within a single sample run. With UPLC,
a run time of 12 minutes can be achieved without significant loss
in sensitivity, covering major monoacyl-glycerols and -phospholi-
pids, diacyl-glycerols and –glycerophospholipids, sphingolipids,
triacylglycerols, and cholesterol esters (Figure 1). The lipid analysis
is the same as described in detail previously [27].
An aliquot (10 ml) of an internal standard mixture containing
equal amounts of, internal standards (GPCho(17:0/0:0),
GPCho(17:0/17:0), GPEtn(17:0/17:0), GPGro(17:0/17:0)[rac],
Cer(d18:1/17:0), GPSer(17:0/17:0), GPA(17:0/17:0) and D-ery-
thro-Sphingosine-1-Phosphate (C17 Base) from Avanti Polar Lipids
and MG(17:0/0:0/0:0)[rac], DG(17:0/17:0/0:0)[rac] and
TG(17:0/17:0/17:0) from Larodan Fine Chemical) and 0.05 M
sodium chloride (10 ml) were added to serum samples (10 ml) and
the lipids were extracted with chloroform/methanol (2:1, 100 ml).
After vortexing (2 min), standing (1 hour) and centrifugation
(10000 RPM, 3 min), the lower layer was separated and a standard
mixture containing 3 labeled standard lipids was added (10 ml) to
the extracts. The standard solution contained 10 mg/ml (in
chloroform:methanol 2:1) GPCho(16:0/0:0-D3), GPCho(16:0/
16:0-D6) and TG(16:0/16:0/16:0-13C3), all from Larodan Fine
Chemicals. The sample order for LC/MS analysis was determined
by randomization.
Lipid extracts were analysed on a Waters Q-Tof Premier mass
spectrometer combined with an Acquity Ultra Performance
LCTM. The column, which was kept at 50uC, was an Acquity
UPLCTM BEH C18 10650 mm with 1.7 mm particles. The
binary solvent system included A. water (1% 1 M NH4Ac, 0.1%
HCOOH) and B. LC/MS grade (Rathburn) acetonitrile/isopro-
panol (5:2, 1% 1 M NH4Ac, 0.1% HCOOH). The gradient
started from 65% A/35% B, reached 100% B in 6 min and
remained there for the next 7 min. The total run time including
a 5 min re-equilibration step was 18 min. The flow rate was
0.200 ml/min and the injected amount 0.75 ml. The temperature
of the sample organizer was set at 10uC.
The lipid profiling was carried out on Waters Q-Tof Premier
mass spectrometer using ESI+ mode. The data were collected at
mass range of m/z 300–1200 with a scan duration of 0.2 sec. The
source temperature was set at 120uC and nitrogen was used as
desolvation gas (800 L/h) at 250uC. The voltages of the sampling
cone and capillary were 39 V and 3.2 kV, respectively. Reserpine
(50 mg/L) was used as the lock spray reference compound (5 ml/
min; 10 sec scan frequency).
Figure 1. Two-dimensional representation of the lipid spectra for a selected illustrative sample obtained by reversed phase Ultra Performance Liquid
Chromatography coupled to high resolution Mass Spectrometry (positive ion mode). Major lipid groups found in different parts of the spectra are
marked. MZmine software [18,19] was utilized for visualization and spectral data processing.
doi:10.1371/journal.pone.0000218.g001
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Tandem mass spectrometry was used for the identification of
selected molecular species of lipids. MS/MS runs were performed
by using ESI+ mode and ESI- mode (to determine fatty acid
composition of phospholipids), collision energy ramp from 15 to
30 V and mass range starting from m/z 150. The other conditions
were as shown above.
Data were processed using MZmine software version 0.60 [28].
Lipids were identified using internal spectral library or with
tandem mass spectrometry. The normalization of lipidomics data
was performed as follows: All monoacyl lipids except cholesterol
esters, such as monoacylglycerols and monoacyl-glycerophospho-
lipids were normalized with GPCho(17:0/0:0), all diacyl lipids
except ethanolamine phospholipids were normalized with
GPCho(17:0/17:0), the diacyl ethanolamine phospholipids were
normalized with GPEtn(17:0/17:0), and the triacylglycerols and
cholesterol esters with TG(17:0/17:0/17:0). Only the identified
lipid molecular species were included in data analyses, unless
otherwise noted.
Chemometric modeling of data
Partial least squares discriminant analysis (PLS/DA) [29,30] was
utilized as a supervised modeling method using SIMPLS algorithm
to calculate the model [31]. As the total number of samples was
insufficient for independent validation, no hold-out dataset was
utilized for cross-validation. Instead, Venetian blinds cross-
validation method [32] and Q2 scores were used to optimize the
model. Top loadings for latent variables were reported. The VIP
(variable importance in the projection) values [33] were calculated
to identify the most important molecular species for the clustering
of specific groups. Multivariate analyses were performed using
Matlab version 7.2 (Mathworks, Inc.) and the PLS Toolbox
version 4.0 Matlab package (Eigenvector Research, Inc.).
Statistical analyses
The statistical comparisons of the subjects were made either
between individuals or between co-twins in a pair. Given that MZ
twins are genetically identical, any differences between the co-
twins must be attributable to acquired factors, including prenatal
and epigenetic effects [11]. Differences in the clinical character-
istics between the co-twins were compared by paired Wilcoxon’s
signed ranks test. Male and female pairs were combined because
MZ co-twins are inherently matched for gender. To analyze the
relationships between lipidomics and clinical measures indepen-
dent of potential genetic confounding, the data were twin-
normalized in all pairs.
Previous studies have shown that the variance of intensities
tends to grow linearly as a function of the intensity levels
(heteroscedasticity) [34]. By taking logarithms of the intensity
values one can eliminate this effect and make the data better follow
a normal distribution with intensity-independent variance. For this
reason, the body composition data were twin-normalized by using
the difference between the heavier and leaner co-twins (based on
BMI) and the biochemical variables by using the difference of
log2-transformed values. Lipidomics data were twin-normalized
by taking the within-pair difference of the log2-transformed
concentration values for each lipid species:
Tit~ log2 Iit1{ log2 Iit2 ð1Þ
where Tit is the twin-normalized lipid intensity, i is the lipid index,
t is the twin pair index (1 denoting the twin with higher BMI, 2
with lower), and Iit1 is the peak height for lipid i of the heavier twin
from pair t. Within-pair similarity was assessed for each lipid
molecular species by a total sum of squares of log differences of
lipid levels within each twin pair, i.e.
SSQi~
XN
t~1
log2 Iit1{ log2 Iit2ð Þ2 ð2Þ
The correlations between the clinical variables and the lipid
profiles were calculated pair-wise using Spearman rank correla-
tions. The reported p-value is the probability of getting
a correlation as large as the observed value by random chance,
when the true correlation is zero. The p-value was calculated using
the large sample approximation. The levels of significance are
marked as *p,0.05, **p,0.01, ***p,0.001. Only correlations
with p,0.15 were reported in figures, unless noted otherwise.
Partial Least Squares method was also applied to regress the lipid
profiles on the clinical variables. Since the results were similar and
conclusions the same as obtained by pair-wise correlation analysis,
these results are not reported.
RESULTS
Clinical characteristics of the co-twins
Physical and biochemical characteristics of the twins are shown in
Table 1. The obese co-twins of the discordant MZ pairs had more
subcutaneous and intra-abdominal fat than the non-obese co-
twins. The obese co-twins also had lower whole body insulin
sensitivity (M-value) and higher fasting serum insulin concentra-
tions than the non-obese co-twins. Fasting serum LDL-cholesterol
and triglyceride concentrations were higher and HDL-cholesterol
concentrations lower in the obese co-twins. Fasting serum CRP
and leptin concentrations were higher and adiponectin concentra-
tions lower in the obese, compared with the non-obese co-twins.
None of these variables differed between the weight-concordant
co-twins (Table 1). The two groups of non-obese individuals (i.e.
the non-obese discordant and the normal weight concordant pairs)
differed from each other. As shown in Table 1, the normal weight
concordant pairs were leaner than the non-obese discordant twins,
having lower BMI (p=0.007), % body fat (p=0.033), sub-
cutaneous (p=0.012) but not intra-abdominal fat (p=0.31), and
lower CRP (p=0.013) and leptin (p=0.027). However, the main
interest in this study was in the within pair comparisons of the
pairs. Compared with the concordant pairs, the discordant pairs
had larger intra-pair differences in BMI (median 5.1 vs. 1.0 kg/m2,
p,0.0001), % body fat (7.3 vs. 2.4%, p=0.0002), subcutaneous fat
(1784 vs. 254 cm3, p=0.0007), intra-abdominal fat (375 vs.
93 cm3, p=0.0049), the M-value (22.9 vs. 0.4 mg?kg fat free
mass21?min21, p=0.016), fasting serum insulin (4.0 vs. 0.5,
p=0.052), leptin (12.0 vs. 0.6 ng/ml, p=0.0004) and adiponectin
(216.5 vs. 3.8 mg/ml, p=0.041), but not in serum total
cholesterol, LDL, HDL, triglycerides or CRP (data not shown).
In the following twin-pair normalized analyses, both concordant
and discordant pars were used, to yield a wide range of intra-pair
differences, from very similar to dissimilar pairs. In the whole
sample, the BMI-differences ranged from 0.01 to 10.1 kg/m2, and
individual BMIs from 20.0 to 45.8 kg/m2.
Relationships between the measures of obesity and other clinical
characteristics were analyzed for each individual separately and
within twin pairs (Figure 2). After twin-pair normalization, i.e.
after controlling for genetic factors, the negative correlations of
different measures of body fat with whole body insulin sensitivity
(the M-value) and adiponectin and positive correlations with
fasting serum insulin and leptin became more pronounced than in
the correlations performed in individual subjects. In addition,
Lipidomics Study in Twins
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twin-pair normalization also resulted in clearer negative correla-
tions of HDL cholesterol with obesity and with insulin sensitivity
than correlations at individual level.
The reported intake of energy and macronutrients was similar
in the co-twins of both the discordant and concordant pairs. In the
discordant pairs, the obese co-twins reported a median daily
consumption of 8554 kJ energy, 78 g fat, 85 g protein and 240 g
carbohydrates. In the non-obese co-twins, the respective values
were 9281 kJ energy, 80 g fat, 82 g protein and 258 g
carbohydrates.
Lipid profiles and obesity
A total of 331 lipid molecular species were detected, of which 133
were identified (Supplementary Dataset S1). Distinct differences
were observed in the global lipid profiles between the obese and
non-obese co-twins in the 14 MZ twin pairs discordant for obesity
(Figure 3A). While the concentrations of most abundant
phospholipids such as phosphatidylcholines were found both
increased or decreased depending on their fatty acid composition,
two consistent trends were found: concentrations of lysopho-
sphatidylcholines (LPCs) were higher and concentrations of ether
phospholipids lower in the obese co-twins (Figure 3B). The
observed differences were not explained by gender (Figure 3A).
Pairwise analyses revealed that LPCs correlated positively with
measures subcutaneous obesity and negatively with insulin
sensitivity (Figure 4A), while the reverse was found for ether
phospholipids (Figure 4B). No consistent relationships were
observed between LPCs or ether phospholipids and intra-
abdominal fat.
We also sought for the lipid species with the least intrapair
variability (SSQ value). Out of all 331 peaks, the five with the
lowest variability were all sphingomyelins (SMs) with very long
chain fatty acids (Table 2). These very long chain fatty acid SMs
had no correlation with body composition, whereas short and
medium chain fatty acid SMs correlated positively with intra-
abdominal fat and insulin (Figure 5).
Body fat distribution and the lipid profiles
We further studied whether serum lipid profiles would differ by
various measures of obesity. Within twin pairs, all fat depots were
negatively correlated with docosahexaenoic acid (22:6, commonly
known as DHA) containing phospholipids and phosphatidylcho-
line molecular species GPCho(38:5) (Figure 6). The measures of
subcutaneous fat shared some features that differed from those of
intra-abdominal fat. BMI, total body fat and subcutaneous fat
correlated positively with long chain triacylglycerol species ($C54)
and negatively with specific phosphatidylcholine species and the
ether phospholipids (Figure 6A–C). Intra-abdominal fat correlated
positively with medium chain sphingomyelin species (Figure 6D).
Insulin sensitivity and the lipid profiles
Many of the same lipids that were previously shown to correlate
positively with measures of subcutaneous fat (Figure 6A–C) were
negatively associated with insulin sensitivity (Figure 7A). LPCs and
triacylglycerol species containing$C54 were associated with poorer
and DHA-containing phosphatidylcholines and ether phospholipids
with better insulin sensitivity. The same sphingomyelin species
SM(d18:1/18:1) that correlated positively with intra-abdominal fat
(Figure 6D), correlated positively with fasting insulin (Figure 7B).
Several other sphingomyelin species containing 18:0, 18:1, and 20:0
fatty acids also correlated positively with insulin.
Table 1. Physical and biochemical characteristics of the 24 monozygotic twin pairs.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pairs discordant for weight (n = 14) Pairs concordant for weight (n = 10)
Normal weight pairs (n = 5) Overweight pairs (n = 5)
Non-obese co-twin Obese co-twin p* Both co-twins Both co-twins
BMI (kg/m2) 25.4 (24.5, 26.1) 30.4 (28.4, 32.5) 0.001 21.5 (20.8, 23.7) 29.3 (26.9, 30.4)
Percent body fat 27.1 (23.3, 38.5) 37.2 (32.6, 43.0) 0.001 19.0 (13.9, 20.7) 34.8 (29.9, 45.8)
Subcutaneous fat (cm3) 2698 (2406, 3966) 4846 (4376, 5821) 0.001 1445 (1234, 1600) 4162 (3675, 5917)
Intra-abdominal fat (cm3) 527 (380, 685) 1010 (827, 1183) 0.001 452 (361, 614) 1059 (626, 1500)
M value (mg?kg fat free mass21?min21) 8.6 (6.6, 10.4) 6.6 (4.9, 7.3) 0.01 8.4 (6.2, 9.8) 6.9 (5.7, 8.0)
Serum insulin (mU/l) 5.0 (3.0, 8.0) 9.0 (6.0, 11.0) 0.02 5.5 (4.0, 6.0) 9.5 (7.0, 10.0)
Serum total cholesterol (mmol/l) 4.6 (4.1, 5.0) 4.7 (4.3, 5.1) 0.41 4.4 (3.9, 5.1) 4.7 (4.4, 5.5)
Serum LDL-cholesterol (mmol/l) 2.5 (2.1, 3.0) 2.6 (2.4, 3.2) 0.030 2.5 (1.5, 2.9) 2.7 (2.3, 3.0)
Serum HDL-cholesterol (mmol/l) 1.3 (1.2, 1.7) 1.3 (1.0, 1.4) 0.012 1.4 (1.1, 2.0) 1.2 (1.1, 1.8)
Serum triglycerides (mmol/l) 1.0 (0.7, 1.2) 1.4 (0.9, 1.6) 0.028 1.0 (0.8, 1.1) 1.6 (0.7, 2.1)
Serum high sensitivity CRP (mg/l) a 0.9 (0.2, 1.1) 2.0 (0.9, 3.4) 0.003 0.2 (0.1, 0.2) 1.4 (0.5, 4.0)
Serum leptin (ng/ml) b 15.1 (7.2, 25.3) 24.1 (18.5, 39.1) 0.003 4.8 (3.6, 6.1) 17.7 (11.1, 39.4)
Serum adiponectin (mg/ml) b 12.7 (9.0, 14.9) 10.8 (6.8, 12.6) 0.013 10.7 (9.2, 11.9) 7.9 (6.9, 9.1)
Data are median (interquartile range). *obese vs. non-obese co-twins, paired Wilcoxon’s test. a n = 19 pairs. b n = 21 pairs.
doi:10.1371/journal.pone.0000218.t001..
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Table 2. The most similar lipids within each twin pair (N = 24).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lipid ID Mean SSQ/N
SM(d18:0/20:0) 0.0145 0.0882
SM(d18:1/22:0) 20.0349 0.0980
SM(d18:1/22:1) 20.0368 0.0744
SM(d18:1/24:1) 20.0363 0.0825
SM(d18:1/24:2) 20.0376 0.0948
doi:10.1371/journal.pone.0000218.t002..
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Correlations of the global lipid profile with classical
lipid parameters
Correlations between lipid molecular species and classical serum
lipids were analyzed in individual twins. The total cholesterol
concentration correlated positively with medium and long chain
triacylglycerols and with specific LPCs, and negatively with the
ether phospholipids (Figure 8A). The HDL cholesterol correlated
poorly with the lipidomic profiles, with only few molecular species
being significantly negatively correlated, none of them triacylgly-
cerols (Figure 8B). The LDL cholesterol had similar correlation
structure as the total cholesterol (Figure 8C) while the total
triglycerides correlated best to specific phosphatidylcholines,
including the DHA-containing GPCho(16:0/22:6), long and
medium chain triacylglycerols, as well as to long chain fatty acid
sphingomyelins (Figure 8D).
Further, the standard serum triglyceride measure correlated
best with the most abundant triacylglycerol species in the
lipidomics profile, while the correlation was negative for several
low abundance triglyceride species (Figure 9A). The total length of
fatty acids (i.e. total number of fatty acid carbons) correlated
positively with the serum total triglyceride concentration, in-
dependently of the degree of fatty acid saturation (Figure 9B).
DISCUSSION
Environmental and lifestyle factors play a key role in metabolic
disorders related to obesity, but it is often very difficult to
disentangle these effects from genetic factors that also influence
both body fat accumulation and lipid metabolism [10]. Studies of
monozygotic (MZ) twins discordant for obesity permit unequivocal
distinction between genetic versus environmental and life-style
effects. The obese and non-obese MZ co-twins are matched not
only for genes but also for age, gender, socioeconomic background
and many intra-uterine and childhood environmental factors. The
present study focused on young and healthy obesity-discordant
MZ twins. We showed that obesity, independent of genetic
influences, was related to distinct changes in the global serum lipid
profile. In comparison to non-obese co-twins, the obese co-twins
had increased levels of lysophosphatidylcholines (LPCs), lipids
found in proinflammatory [35,36] and proatherogenic conditions
[37] and decreases in ether phospholipids, which are known to
have antioxidant properties [38,39]. These lipid changes were
associated with insulin resistance, a pathogonomic characteristic of
the obese co-twins. Our data strongly suggest that obesity-related
non-genetic factors make a major contribution to the pre-
atherosclerotic and pre-diabetic lipid alterations.
LPCs’ proinflammatory and atherogenic properties have been
demonstrated in previous studies. These phospholipids upregulate
a range of proinflammatory molecules such as P-selectin [40],
matrix metalloproteinase-2 [41], cytokines [42,43], and superox-
ide anions [44,45]. LPC increases the permeability of vascular
endothelium [46], the process believed to be mediated by a novel
subfamily of G protein-coupled receptors (GPR4, G2A, OGR1,
and TDAG8) [47]. Increased LPC levels are found in patients with
type 2 diabetes [48] and atherosclerosis [49]. In a recent study we
have also shown that the LPC levels are elevated in obese Zucker
rats at 8 weeks of age relative to lean controls and that PPARc
agonist pioglitazone treatment lowers GPCho(18:0/0:0) to levels
found in lean Zucker rats [50].
The physiological functions of ether phospholipids are less well
understood. There is growing evidence that plasmalogens, the
most abundant ether phospholipid subclass characterized by the
vinyl-ether bond in sn1 position, can serve as endogenous
antioxidants [39]. Plasmalogens may also have a crucial role in
states of increased oxidative burden such as hypoxia [51]. Galili
and colleagues found recently that increased LPC levels in early
obesity in young pigs are associated with endothelial dysfunction
and oxidative stress [52]. The combination of high LPC and low
ether phospholipid concentration in the present study suggests that
LPC and oxidative stress may be linked also in human obesity.
LPCs and ether phospholipids had opposite associations with
the M-value, a measure of insulin sensitivity. It is possible that
these lipids act as signaling molecules in the insulin cascade. In line
with this hypothesis are recent data in rat vascular smooth muscle
cells showing that LPC impairs insulin stimulation of insulin
receptor substrate (IRS)-1 tyrosine phosphorylation and coupling
of the insulin receptor pathway to Akt activation through protein
kinase C-a [53]. The role of ether phospholipids in insulin
sensitivity remains speculative. The decreases in ether phospho-
lipids in obese co-twins could be due to an increased handling of
reactive oxygen species (ROS). High ROS production, rather than
low ether phospholipid concentration itself, may then be the factor
negatively regulating insulin signaling [54]. Two possible scenarios
have been proposed for the lowering of plasmalogens concentra-
tions [55]: (1) Free radical attack to the vinyl-ether bond of
plasmalogens, or (2) receptor-mediated degradation by plasmalo-
gen-selective phospholipase A2 (psPLA2). Our data supports the
latter scenario since ether linked LPCs such as GPCho(O-20:3/
Figure 2. Correlation maps for clinical variables. (A) Each individual
considered separately (N= 48). (B) Twin pair normalized (N= 24).
doi:10.1371/journal.pone.0000218.g002
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Figure 3. Partial least squares discriminant analysis (PLS/DA) of lipidomics profiles for obesity discordant co-twins, utilizing only the 133 identified
peaks and two classes (obese and non-obese co-twins) to build the model. Three latent variables were used (Q2 = 47%). (A) PLS/DA score plot.
Genders and twin-pair identifiers are marked for each sample, although this information was not used to build the model. (B) Fold changes for most
important variables based on VIP analysis contributing to the PLS/DA model.
doi:10.1371/journal.pone.0000218.g003
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Figure 4. Twin-normalized Spearman rank correlations of (A) two most abundant lysophosphatidylcholine and (B) ether phospholipid species with
clinical variables. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0000218.g004
Figure 5. Correlation plots for selected sphingomyelin species and clinical variables in (A) individual twins, and (B) twin pairs.
doi:10.1371/journal.pone.0000218.g005
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0:0), products of PLA2 action, were also found upregulated in
obese co-twins (Figure 3).
It is of interest that a docosahexanoic acid (DHA)-containing
phosphatidylcholine GPCho(16:0/22:6) correlated strongly nega-
tively with the amount of both subcutaneous and intra-abdominal
fat (Figure 6) and positively with insulin sensitivity (Figure 7). DHA
is an essential n-3 fatty acid with known health benefits [56] but
the molecular mechanisms behind its health benefits are poorly
understood. Some recent evidence suggests that dietary poly-
unsaturated fatty acids such as DHA significantly alter the
membrane functionality composition of caveolae [57]. Caveolae,
specialized membrane microdomains enriched in cholesterol,
sphingolipids, and their coat protein caveolin-1, have been
implicated in augmentation of insulin signaling [58]. Although
found in a variety of cell types, caveolae are most abundant in
adipose tissue. Positive correlations of GPCho(16:0/22:6) with the
M-value and negative correlations with insulin in the present study
suggest that DHA containing lipids indeed participate in insulin
signaling. Whether the seeming deficiency of serum DHA in
obesity reflects the composition of adipose tissue or is related to
dietary changes remains to be elucidated.
In addition to many similarities across various fat depots, we
also found considerable differences in the lipid profiles associated
with various fat depots. Measures of subcutaneous obesity (BMI,
total body fat and subcutaneous abdominal fat) correlated with
a similar lipid profile whereas intra-abdominal fat had additional
specific features. Subcutaneous obesity correlated positively with
serum long chain triacylglycerols and negatively with phosphati-
dylcholine and ether phospholipids within twin pairs. In contrast,
intra-abdominal fat correlated positively with medium chain
sphingomyelin species. Interestingly, it has recently been demon-
strated that adipose sphingolipid metabolism is altered and plasma
levels of total sphingomyelin, ceramide, sphingosine, and sphin-
gosine 1-phosphate (S1P) are elevated in genetically obese (ob/ob)
mice [59]. Whether the observed changes in the lipid profile and
their relationships with adipose tissue distribution can predict
insulin resistance and atherosclerosis on an individual basis in
humans needs to be studied further.
Figure 6. Twin-normalized Spearman rank correlations of lipids with different fat depots: (A) BMI, (B) total body fat, (C) subcutaneous fat, and (D)
intra-abdominal fat. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0000218.g006
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Obesity did not affect all lipids in serum. Despite the up to 25 kg
differences in weight, the very long chain fatty acid (VLCFA)
sphingomyelins were very similar in the co-twins (Table 2).
Biosynthesis of VLCFA occurs by carbon chain elongation of
shorter chain fatty acid precursors. Their b-oxidation, a process
controlled by peroxisome proliferator activator receptors (PPARs)
[60], takes place almost exclusively in peroxisomes [61]. Our
results therefore suggest that the observed proinflammatory
changes in early obesity precede the lipotoxic phenomena
hallmarked by overflow of saturated fatty acids and dysregulation
of the PPAR regulatory system [62].
We also examined how the lipid profile changes reflect
differences in classical serum lipid values. Serum triglyceride
levels correlated positively with most detected phospholipids and
acylglycerols, reflecting the association with the increased flux of
these species from the liver in the format of VLDL particles.
Interestingly, DHA containing lipids were among the lipids most
significantly correlated with classical lipid parameters. This may
reflect the rapid incorporation of dietary n-3 fatty acids into the
liver nuclei [63] and subsequent release to serum in the lipoprotein
particles. Serum LDL concentrations associated positively with
LPCs and negatively with ether phospholipids. This supports the
Figure 7. Twin-normalized Spearman rank correlations of lipids with (A) M-value and (B) insulin. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0000218.g007
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proatherosclerotic nature of LDL, especially in its oxidized form.
In oxidized LDL, the ratio of LPC to total glycerophosphocholine
content increases to 50% from the normal ratio of 1–5% [64].
However, the major carrier of human plasma LPC is albumin
[65], demonstrating that the serum global lipid profiles are to an
extent unrelated to the classical lipid concentrations.
We might ask why are these MZ twin pairs so strikingly
discordant for obesity? Like other MZ pairs in our base
population, their growth and weight development was normal in
childhood and adolescence. The intra-pair weight differences
began to appear only after puberty [17]. This might suggest that
the proximate cause(s) of their obesity relates to changes after mid-
adolescence, possibly related to differences in their individual life-
styles; those differences are not necessarily present after the
development of obesity. Therefore prospective studies initiated
prior to onset of obesity, preferably in genetically controlled
populations, would be needed to conclusively identify environ-
mental causes. It is also possible that the development of obesity is
related to an epigenetic modification of gene expression in these
MZ pairs. Fraga et al. [66] suggested that epigenetic changes
increase with increasing age in trait discordant MZ pairs.
However, the epigenetic effects relevant to obesity may also
develop in childhood or even prenatally. One can speculate that
specific environmental factors such as dietary components or
sustained physical inactivity could induce development of obesity
through modulation of expression of genes regulating satiety [67],
as has been shown for social stress and genes affecting depression
[65]. Once excess weight development sets in, physical inactivity
increases and a vicious circle is ready. What we see in the current
analyses are the consequences of this process, but one cannot
exclude the possibility that one or more of the lipid species play
a causal role in the development of obesity.
Figure 8. Correlations with classical lipid parameters using Spearman rank correlations across all individuals (N= 48). Only lipids with p,0.1 are
reported for triglyceride and total cholesterol correlations. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0000218.g008
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One limitation of the present study is the relatively small sample
size. Despite a population-based screening of five full birth cohorts
of young adult twins, only 14 MZ pairs highly discordant for
obesity were found. This is consistent with the evidence that
obesity is significantly influenced by genetic factors. Another
potential limitation is the fact that the normal weight concordant
twins were leaner than twins from other study groups. However,
the two main focuses in the study were (a) to compare obese and
non-obese twins from discordant pairs and (b) to assess the
correlations between intra-pair differences in the clinical measures
and those in the lipidomic profiles. Due to a wide range of intra-
pair differences in BMI from 0 to 10 kg/m2 the subject selection
was suitable for this purpose.
In conclusion, our data provide evidence on significant changes of
the global serum lipid profile in obesity, independent of genetic
influences. Acquired obesity was characterized by increased
concentrations of proatherogenic and proinflammatory lysopho-
sphatidylcholine species and decreased concentrations of anti-
oxidative ether phospholipids in serum. These lipid changes could
account for many of the previously recognized links between obesity
and accelerated atherosclerosis. Importantly, the above changes in
the global serum lipid profile were associated with insulin resistance,
a pathogonomic characteristic of acquired obesity in these pre-
sumably healthy young adults. It is likely that proper management of
obesity, perhaps with a new generation of therapies directed at
several targets in the lipid metabolism pathways, will correct these
abnormalities, and favorably modify the risk, course and outcome of
diabetes and cardiovascular diseases.
SUPPORTING INFORMATION
Dataset S1 Lipidomics dataset and clinical variables
Found at: doi:10.1371/journal.pone.0000218.s001 (0.16 MB
XLS)
Figure 9. Correlation of serum triglyceride measure with different triacylglycerol species as a function of (A) the amount, and (B) the number of fatty
acid carbons.
doi:10.1371/journal.pone.0000218.g009
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